Pteridinone derivatives for use as stearoyl CoA desaturase...

Details Pteridinone derivatives for use as stearoyl CoA desaturase... Pteridinone derivatives for use as stearoyl CoA desaturase...

2007-10-05

2010-02-16

Berch, Mark L (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C544S258000, C544S326000, C544S329000, C544S328000, C544S323000

Reexamination Certificate

active

07662819

ABSTRACT:
The present invention discloses pteridinone derivatives for use as inhibitors of stearoyl-CoA desaturase having the structure of Formula I:The compounds are useful in treating and/or preventing various human diseases, mediated by stearoyl-CoA desaturase (SCD) enzymes, especially diseases related to abnormal lipid levels, cardiovascular disease, diabetes, obesity, metabolic syndrome and the like.

REFERENCES:
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 4326525 (1982-04-01), Swanson et al.
patent: 4992445 (1991-02-01), Lawter et al.
patent: 5001139 (1991-03-01), Lawter et al.
patent: 5023252 (1991-06-01), Hseih
patent: 5616345 (1997-04-01), Geoghegan et al.
patent: 2004/0019210 (2004-01-01), Connolly et al.
patent: 2008/0139570 (2008-06-01), Chisholm et al.
patent: WO 99/50254 (1999-10-01), None
patent: WO 01/19825 (2001-03-01), None
patent: WO/2001/19825 (2001-03-01), None
Griesser, Chapter 8, The Importance of Solvates (pp. 211-230), in the text, Polymorphism: In the Pharmaceutical Industry, Hilfiker, 2006.
Brittain, Chapter V, Polymorphism in Pharmaceutical Solids, 1999, pp. 126-127.
Chow, et al., Can. J. Chem., vol. 63, 1985, 2203-2210.
Cui, et al., J. Pharm. Sci., vol. 97, # 7, 2730-2744, Jul. 2008.
Chisholm, J. et al., “The LXR Ligand T0901317 Induces Severe Lipogenesis in the db/db Diabetic Mouse”,Journal of Lipid Research, vol. 44, No. 11, 2003, pp. 2039-2048.
Ntambi et al. (2004)Prog Lipid Res43, 91-104; (2005).
A. Dobrzyn and J.M. Ntambi,Obes. Rev.6, (2005), 169-174.
Jiang et al.Prevention Of Obesity In Mice By Antisense Oligonucleotide Inhibitors Of Stearoyl-CoA Desaturase-1(2005)J. Clin. Invest. 115:1030-1038.
Gutiérrez-Juárez et al.Critical Role Of Stearoyl-CoA Desaturase-1(SCD1)In The Onset Of Diet-Induced Hepatic Insulin Resistance(2006)J. Clin. Invest. 116:1686-1695.
A. Dobrzyn and J.M. Ntambi,Prostaglandins Leukot. Essent. Fatty Acids73, 35-41; (2005).
Talamo and Bloch (1969)Analytical Biochemistry29:300-304.
Gutiérrez-Juárez et al.Critical Role Of Stearoyl-CoA Desaturase-1(SCD1)In The Onset Of Diet-Induced Hepatic Insulin Resistance(2006)J. Clin. Invest. 116:1686-1695, 2006.
A. Dobrzyn and J.M. Ntambi,Prostaglandins Leukot. Essent. Fatty Acids73, 35-41, 2005.
Remington's Pharmaceutical Sciences, Mace Publishing Co., Philadelphia, PA 17thEd. (1985).

Affiliated with

Also associated with

Rating

Pteridinone derivatives for use as stearoyl CoA desaturase... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pteridinone derivatives for use as stearoyl CoA desaturase..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pteridinone derivatives for use as stearoyl CoA desaturase... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4179142